PTEN: a molecular target for neurodegeneratIve dIsorders abstract PTEN (phosphatase and tensin homologue deleted in chromosome 10) was first identified as a candidate tumour suppressor gene located on chromosome 10q23. It is considered as one of the most frequently mutated genes in human malignancies. Emerging evidence shows that the biological function of PTEN extends beyond its tumour suppressor activity. In the central nervous system PTEN is a crucial regulator of neuronal development, neuronal survival, axonal regeneration and synaptic plasticity. Furthermore, PTEN has been linked to the pathogenesis of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Recently increased attention has been focused on PTEN as a potential target for the treatment of brain injury and neurodegeneration. In this review we discuss the essential functions of PTEN in the central nervous system and its involvement in neurodegeneration. 
Introduction
as Cowden disease (CD) [4] , Lhermitte Duclos disease (LDD) [5] , and Bannayan-Zonana syndrome (BZS) [6] . These syndromes share characteristic developmental defects, benign tumours and increased susceptibility to thyroid and breast malignancies.
The PTEN gene consists of nine exons and encodes a 5.5kb mRNA [2] . It encodes a protein consisting of 403 amino acids with a relative molecular weight of 47 kDa [2] . Analysis of PTEN's crystal structure revealed that it consists of three main domains [7] . The amino terminal end (N -terminal), comprising 190 amino acids, carries the signature motif HCXXGXXR, which defines the family of protein tyrosine phosphatases (PTP) and dual specificity protein phosphatases (DSP). Within this motif, the Cys-124 and Arg-130 are essential for the catalytic function of the protein [7] . Most of the mutations are found to affect the N-terminal ( Figure 1 ). Sequence analysis revealed that the catalytic amino terminal end bears homology to chicken tensin [2] , an actin binding protein found in focal adhesions, and bovine auxillin [2] , a protein which disassembles clathirincoated vesicles. The evidence suggests that the N-terminal has additional roles to that of a phosphatase. The C-terminal domain (carboxyl terminal) consists of a C2 domain, which mainly functions in the binding of PTEN to the phospholipids in the plasma membrane [7] . The C-terminal domain also consists of a PDZ-binding motif which is responsible for protein-protein interactions [8] and two PEST sequences [9] . A known role for PEST sequences is to target proteins for proteolytic degradation. In contrast, studies have shown that PEST sequences play a role in the stability of the PTEN protein [9, 10] . Finally, the tail of PTEN consists of 50 amino acids which is also essential for PTEN stability [7] .
The discovery of PTEN in 1997 stimulated several research groups to identify its substrates.
The finding by Mahaema and Dixon, that
PTEN is a phosphatidylinositol phosphatase, was a major step towards the understanding of its function [11] . PTEN dephosphorylates specifically at position 3 of the inositol ring. PTEN opposes phosphatidylinositol 3 kinase (PI3K) and thus negatively regulates the pathway [11] . The PI3K/AKT signalling pathway has been widely reviewed (see review [12] ).
Briefly, binding of growth factors to receptor
tyrosine kinases causes activation of PI3K which catalyses the phosphorylation of phosphatidyl-inositol 2 (PIP2) to generate the production of phosphatidyl-inositol 3 (PIP3) [13] . Generation of PIP3 results in the recruitment of the cytosolic protein, AKT, also known as PKB (protein kinase B), to the plasma membrane where it is activated and phosphorylated by phosphoinositide-dependent kinase-1 (PDK1) [14] . AKT is an essential mediator of several signalling pathways including cell survival, glucose metabolism and protein translation [15] . It exists in three isoforms: AKT1, AKT2
and AKT3 [15, 16] . AKT3 is most abundant in the brain and testis [16] . AKT exerts its role as a cell survival and proliferation mediator by phosphorylating various downstream signals including: bcl2 antagonist of cell death (BAD) [1] , glycogen synthase kinase 3-β (GSK3-β) [17] , forkhead transcription factors (FHTR) [18] , caspase-9 [19] , nuclear factor-kappaB (NF-κB) [20] and mammalian-target-of rapamycin (mTOR) [21] . Of these targets, BAD is one of the from phosphatidyl-inositol-2 (PIP2). The production of PIP3 leads to the translocation of AKT from the cytoplasm to the cell membrane where it becomes phosphorylated and activated at Ser473 and THr308. Activated AKT phosphorylates several cytoplasmic substrates and regulates protein translation, glucose metabolism and inhibits apoptosis. PTEN dephosphorylates PIP3 and acts as a main negative regulator of the PI3K/AKT pathway. and mTOR complex 2 (mTORC2) [22] . mTOR regulates key cellular processes such as protein synthesis [22] , autophagy [23] , mitochondrial metabolism and biogenesis [22] , which play an essential role in maintaining the integrity of postmitotic neurons (for a detailed description of mTOR signalling see review [22] ). Defects in autophagy have been linked to neurodegeneration in conditions such as Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS) [23] . Of interest, rapamycin, a selective inhibitor of mTORC1, was shown to be neuroprotective in experimental models of ALS [24] , PD [25] and AD [26] . insulin signalling related to obesity [29] . They also showed that GSK-3β regulates PTEN by phosphorylation at position 366 priming site as a novel feedback mechanism [30] . In addition several studies have shown that PTEN negatively regulates the MAPK pathway, another important pathway in cell survival and proliferation [31, 32] .
Initially, much of the research focused on PTEN's role in the molecular pathogenesis of glioblastoma. This has unravelled a broader role for PTEN in the nervous system. In this review we will discuss the crucial functions of PTEN in the central nervous system (CNS) and the role of PTEN in neurodegenerative disorders.
Pten in neuronal development
PTEN is widely expressed in the CNS where it localises to the cytoplasm and nucleus [33, 34] . In Drosophila melanogaster, studies have demonstrated that PTEN regulates cell size, survival and proliferation during the development of the eye and wing [35, 36] . To study the biological functions of PTEN during normal development in the mammalian system, PTEN knockout mice were generated by three independent groups [28, 37, 38] . Di Cristofano et al generated transgenic mice harbouring a loss of function mutation targeting exon 4 and 5 of the mouse PTEN gene [37] . The mice did not survive beyond 7.5 embryonic days. Suzuki's group targeted exon 3-5, and the mutant mice died by 9.5 embryonic days. The mice displayed enlarged caudal and cephalic regions [38] . In To further explore the biological functions of PTEN during brain development, several research groups generated conditional PTEN knockout mice using the cre-lox technology.
For example, PTEN loxp-/-mice were crossed with mice harbouring a nestin-promoter driven
Cre transgene, which is mainly expressed in neuronal precursors by midgestation [40] . This 
Pten and neuronal apoptosis
The lack of apoptosis in brain tumours associated with PTEN mutations raised an increasing interest in a possible role for PTEN in neuronal apoptosis. In vitro models of postmitotic neuronal cell death have shown that PTEN expression is altered in response to various apoptotic inducers [45] . For example, in primary cultured cerebellar granules serum withdrawal with potassium deprivation reduced the expression of PTEN mRNA [45] . While okadeic acid induces an initial increase in PTEN mRNA, this was followed by a reduction in PTEN expression [45] . Similar effects of serum withdrawal were also seen in cultured Neuroblastoma-2a cells [45] . Thus it seems that the reduction in PTEN expression to alcohol during gestation [47] . In this model the mice showed marked cerebellar hypoplasia and cell death indicating a correlation of PTEN with neuronal death [47] . In primary hippocampal neurons, over expression of wild type PTEN, decreased AKT expression and increased glutamate induced cell death [48] .
On the other hand, over expression of mutant PTEN, increased AKT levels and significantly increased neuronal survival [48] . In addition PTEN +/-mice showed increased resistance to death induced by glutamate excitotoxicity [48] . In vitro, perioxynitrate mediates it neuroprotective effects by down regulating PTEN [49] . In line with these findings, it has been shown that hypothermia preserved the levels of phosphorylated PTEN, and attenuated the decrease in active p-AKT, leading to neuroprotection against ischemic injury [50] .
Moreover there is accumulating evidence suggesting that downregulation of PTEN is neuroprotective in ischemic brain injury [51] .
Although these studies clearly demonstrate the involvement of PTEN with neuronal apoptosis, the molecular mechanisms Further studies revealed that lactacyctin was associated with caspase 3 activation which induced the cleavage of PTEN to its truncated form [54] . Moreover, apoptosis induced in rat hippocampal cultures using staurosporine (STS) causes release of cytochrome c and activates caspase 3 and release of reactive oxygen species (ROS) [56] . In the latest study, 
Pten and axonal regeneration

PTEN modulates other factors such
as GSK3-β which also enhances axonal
regeneration. An important observation by
Jiang and colleagues was that inhibition of PTEN increased the number of growing axons
in differentiating hippocampal neurons [60] .
Activation of AKT and inhibition of GSK3-β, played a critical role in axonal growth [60] . In agreement with these findings, the increase in axonal length of hippocampal neurons induced by nerve growth factor (NGF) is mediated by the activation of casein kinase II (CK2), which phosphorylates and inhibits PTEN [61] .
Recent studies revealed that the concomitant deletion of PTEN and suppressor of cytokine signalling 3 (SOC3) enhances a sustained axonal regeneration with an ability of axons to extend over long distances [62] . Furthermore PTEN deletion combined with induced intraocular inflammation also promotes axonal regeneration [63] . Hence
PTEN acts synergistically with other factors to
promote axonal regeneration.
Our team has recently reported that PTEN
protein is enriched in motor neuron growth cones [64] . The same study revealed that PTEN depletion in purified spinal motor neurons of wild type mice enhances axonal growth and resulted in an increase in the size of growth cones [64] . In line with previous studies, this correlated with activation of the mTOR pathway. We have replicated these findings in purified motor neuron cultures from transgenic mouse models of spinal muscular atrophy (SMA). In addition we observed that PTEN deletion restored the levels of β-actin in growth cones [64] .
Several studies have shown that PTEN is involved with synaptic development and plasticity. One study demonstrated that a 34 kDa fragment of PTEN was localised to the mouse neuronal dendrites [65] . In the weaver mouse model, PTEN was absent in Purkinje dendrites where there is defective synaptogenesis [65] . Moreover transgenic mice with conditional deletion of PTEN in the brain had enlarged dendrites and axons with defective synaptic transmission indicating a role for PTEN in synaptic plasticity [66] . Early genetic studies have linked late-onset AD (LOAD) to a locus on chromosome 10 where the PTEN gene is located [74] . However, further gene association studies showed that there was no association between PTEN polymorphisms and LOAD [75] . Griffin et al was the first to report dysfunction of PTEN signalling in AD [76] . They studied human brain autopsies of patients with AD and compared them with non-affected controls. They demonstrated that in AD, there is a loss of cytosolic AKT associated with increased recruitment of AKT to the particulate fractions [76] . This lead to a significant increase in AKT activation, which was detected in the early stages of AD and correlated positively with the disease stage suggesting a possible link with disease progression [76] . In the temporal cortex, they detected significant reductions in PTEN levels and loss of nuclear PTEN which also correlated positively with disease severity.
Recent work has shown that PTEN may be inactivated by S-nitrosylation in AD and this may account for the loss of PTEN observed [77] .
Furthermore, in AD brains, PTEN was found to accumulate in intracellular fibrillary tangles, and co-localises with tau and senile plaques [78] . In accordance with these data, in vitro studies showed that over expression of wildtype PTEN reduces tau phosphorylation and aggregation indicating that PTEN protects against tau induced neurodegeneration [56, 79] . Other studies failed to replicate these findings, and in contrast, reductions in the phosphorylated PTEN (inactive form) was found in some AD brains [80] .
It is evident that deregulation of PTEN may contribute to neurodegeneration in AD. 
Pten and motor neuron disorders
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterised by selective degeneration of motor neurons and ultimately leading to death of patients within 3-5 years. The breakthrough discovery of superoxide dismutase 1 (SOD1) mutations in familial forms of ALS led to the generation of experimental mouse models that broadened our understanding of this complex neurodegenerative disorder [81] . Motor neuron cell death is a characteristic feature of ALS [82] .
Although the role of apoptosis in ALS remains controversial, there is increasing evidence suggesting disequilibrium between pro-and anti-apoptotic factors leading to motor neuron death [82] . The selective vulnerability of motor neurons and the possible involvement of apoptosis suggest neuron specific regulations of survival signalling pathways. To date there is no definitive treatment for ALS. Thus understanding the signalling pathways leading to motor neuron degeneration is pivotal to identify novel therapeutic targets.
Early genetic studies have shown that molecules of the PI3K/AKT pathway are unregulated in response to motor neuron injury [83, 84] . Further attempts to explore the signalling pathways in motor neuron injury proved that AKT plays an important role in mTOR neuronal survival and regeneration [85] .
Cultured motor neurons deprived of trophic factors showed reduced PI3K activity and reduced levels of active AKT [86] . Moreover, transgenic mice over expressing bcl-2, an antiapoptotic protein, were resistant to motor neuron injury. Furthermore, several studies have shown that increased motor neuron survival in ALS in response to trophic factors such as VEGF [87] [88] [89] , IGF-1 [90, 91] , GDNF [92] and ghrelin [93] was mediated by the activation of the PI3K/AKT pathway.
Considering the importance of the PI3K
signalling pathway in motor neuron survival, it is not surprising that increased attention has been focused to study the role of this pathway in ALS.
Observations from several studies in human post-mortem tissue of ALS patients hint to a possible deregulation of the PI3K/AKT pathway. This hypothesis appears to be supported by our studies which demonstrated that targeted deletion of PTEN in vitro models of ALS [94] and SMA [64] significantly enhances the survival of transgenic SOD1
G93A and SMA motor neurons [64] . It is reasonable that attempts to activate this pathway or over express its anti-apoptotic components should be explored to identify new treatment strategies.
Loss of active AKT was also observed in presymptomatic transgenic models of ALS, which remained to the end stages of the disease [96] . In addition, contradictory to the data from human studies, reduced PI3K protein levels were detected in pre-symptomatic mouse models which may account for the selective vulnerability of motor neurons [97, 98] . The discrepancy in these findings with the human studies could be attributed
to differences in models whereby the disease in mouse models is rapidly progressive. An brains [25, 103] . In experimental models of PD,
6-hydroxydopamine (6-OHDA) a widely used PD mimic, inhibits the phosphorylation of GSK3
and AKT, which correlates with dopaminergic neuronal death [104] . This indicates that components of the PI3K/AKT pathway mediate the neurotoxic effects of 6-OHDA [104] . On the other hand, in neurotoxin models of PD, overexpression of AKT lead to neuroprotection from neuronal loss and axonal degeneration in dopaminergic neurons [105] . PD is also characterised by aggregation of the α-synuclein protein [106, 107] . However the β-synuclein protein was found to directly interact and activate AKT, resulting in neuroprotection against neurotoxins that target the striatonigral system [108] . In addition, the neuroprotective effects of NGF in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) models of PD were also mediated by AKT activation [109] .
Loss of function mutations in DJ-1 and Parkin genes have been detected in some familial cases of PD [110] . Although the functions of DJ-1 remains unclear, it is a known PTEN regulator whereby it inhibits its activity [111] .
Targeted deletion of DJ-1 in dopaminergic neurons of Drosophila, leads to neuronal death and dopaminergic dysfunction [112] . Deletion of DJ-1 is associated with the release of ROS and an increased sensitivity to oxidative stress and was paralleled by inhibition of the PI3K pathway. Overexpression of PI3K attenuated the phenotype produced by DJ-1 deletion [112] . Similarly, inhibition of parkin is also associated with a suppression of the PI3K pathway [112] .
In cultures of human dopaminergic SH-SY5Y cells, PTEN deletion rescued the neurotoxicity induced by MPP+ and reduces the release of
ROS.
To further explore the role of PTEN in PD, two groups generated transgenic mice with conditional deletion of PTEN in the dopaminergic system, and both models shared similar phenotypes [113] . In the first model, PTENloxP mice were mated with Slc6a3Cr transgenic mice carrying the cre -recombinase transgene, driven by the dopamine transporter (DAT) promoter for specific deletion in dopaminergic neurons by embryonic day 15 [113] . At this stage, the dopaminergic neurons have fully differentiated. PTEN-null neurons exhibited an increased soma size and dendrite thickness as well as increased cell number.
Moreover PTEN depletion was found to protect against 6-OHDA mediated dopaminergic neurotoxicity [113] . The second research group crossed PTENloxP mice with transgenic mice with tifla deletion, a crucial ribosomal RNA transcription factor, leading to suppression of mTOR and a phenotype which mimic PD.
The mice exhibited a similar phenotype to the first described model [114] , and showed PTEN has been demonstrated to play a critical role in the regulation of neuronal development, axonal growth and regeneration, synaptic plasticity, neuronal survival and differentiation [117] . The functions of PTEN are mediated by the PI3K/mTOR [58] and MAPK [31, 32] pathways. 
